.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Express Scripts
Julphar
Healthtrust
Chinese Patent Office
Federal Trade Commission
Fish and Richardson
QuintilesIMS
Cipla

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,039,474

« Back to Dashboard

Summary for Patent: 8,039,474

Title:2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists
Abstract: The invention relates to novel tetrahydro-1H-carbazole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds to patients.
Inventor(s): Fecher; Anja (Basel, CH), Fretz; Heinz (Riehen, CH), Riederer; Markus (Liestal, CH)
Assignee: Actelion Pharmaceutical Ltd. (Allschwil, CH)
Application Number:11/722,095
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 8,039,474

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/EP2004/014719Dec 27, 2004
PCT Information
PCT FiledDecember 22, 2005PCT Application Number:PCT/IB2005/054380
PCT Publication Date:July 06, 2006PCT Publication Number: WO2006/070325

International Patent Family for Patent: 8,039,474

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
BrazilPI0519280► Subscribe
Canada2594280► Subscribe
China101084190► Subscribe
Cyprus1112376► Subscribe
Denmark1833791► Subscribe
European Patent Office1833791► Subscribe
Spain2369782► Subscribe
Hong Kong1111698► Subscribe
CroatiaP20110773► Subscribe
Israel184233► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Fuji
Merck
Chinese Patent Office
US Department of Justice
Harvard Business School
Moodys
Novartis
McKinsey
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot